Recently, Hangzhou LinkZill Technology Co., Ltd. announced the completion of a multi-million A round financing, exclusively led by Binlingxing Venture Capital. ZhenFund previously led the company’s Pre-A round and continued to increase its investment during the Pre-A+ round.

Founded in 2019, LinkZill is headquartered in Hangzhou, with an R&D and business center in Cambridge, UK. In 2023, the company invested in the construction of its TFT (Thin-Film Transistor) Semiconductor R&D Center in Hangzhou, focusing on the industrial applications of this technology in life sciences, novel sensors, and displays. Currently, LinkZill serves over 300 global clients, spanning more than 20 countries and regions, and has been recognized as a national high-tech enterprise and a Zhejiang Province "Specialized, Refined, and New" SME.

LinkZill was the first to apply TFT semiconductor technology in the DNA synthesis field, launching the world’s first TFT-chip-based DNA synthesis terminal device, the desktop TFT-DNA synthesizer. This product not only innovates the DNA synthesis technology path but also mitigates risks associated with chip trade barriers, fully leveraging the industrial chain advantages of China’s TFT semiconductors, making the TFT semiconductor chip a low-cost, large-area, and mass-producible consumable for life science equipment.

LinkZill has successfully commercialized its products, from terminal equipment and chip consumables to synthesized products: delivering angel customers with three product forms—oligonucleotide microarrays, oligonucleotide pools, and genes. The company has also launched its first standardized product—Zhirui TruArray™ Std 4K high-throughput oligonucleotide microarray.

Looking ahead, LinkZill will continue to deepen its work in TFT underlying technologies, building a more comprehensive, fully domestically produced, and independently controlled life science equipment ecosystem. The company aims to create a complete life science toolchain that serves fields such as synthetic biology, innovative drug research and development, high-throughput biotechnology, and point-of-care testing (POCT).